HilleVax (NASDAQ:HLVX) Cut to Hold at Leerink Partnrs

Leerink Partnrs downgraded shares of HilleVax (NASDAQ:HLVXFree Report) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

A number of other research analysts also recently issued reports on HLVX. HC Wainwright reissued a neutral rating and issued a $2.00 price objective (down from $28.00) on shares of HilleVax in a research note on Tuesday. Guggenheim downgraded shares of HilleVax from a buy rating to a neutral rating in a research report on Monday. Stifel Nicolaus downgraded shares of HilleVax from a buy rating to a hold rating and dropped their target price for the company from $34.00 to $3.00 in a research report on Tuesday. SVB Leerink downgraded shares of HilleVax from an outperform rating to a market perform rating and decreased their price target for the company from $28.00 to $2.00 in a research note on Tuesday. Finally, JPMorgan Chase & Co. reissued a neutral rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research report on Monday. Six research analysts have rated the stock with a hold rating, According to MarketBeat.com, HilleVax has a consensus rating of Hold and an average target price of $9.20.

Get Our Latest Analysis on HLVX

HilleVax Stock Up 3.0 %

HilleVax stock opened at $1.69 on Tuesday. The firm has a market cap of $84.03 million, a price-to-earnings ratio of -0.51 and a beta of 0.78. HilleVax has a 52-week low of $1.55 and a 52-week high of $20.22. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.92 and a current ratio of 10.92. The firm has a 50 day moving average price of $13.28 and a two-hundred day moving average price of $14.68.

HilleVax (NASDAQ:HLVXGet Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). Equities analysts predict that HilleVax will post -3.14 EPS for the current year.

Insider Activity

In related news, Director Aditya Kohli sold 6,000 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total value of $88,380.00. Following the sale, the director now owns 764,878 shares in the company, valued at approximately $11,266,652.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 12,898 shares of company stock worth $193,766 over the last three months. 71.10% of the stock is currently owned by insiders.

Institutional Trading of HilleVax

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Catalys Pacific LLC bought a new position in shares of HilleVax in the fourth quarter valued at approximately $21,009,000. Franklin Resources Inc. raised its position in HilleVax by 4.1% in the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after buying an additional 71,938 shares during the last quarter. abrdn plc bought a new position in HilleVax during the 4th quarter valued at $433,000. SG Americas Securities LLC purchased a new position in HilleVax during the 4th quarter worth $139,000. Finally, Swiss National Bank boosted its holdings in HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after acquiring an additional 7,000 shares during the last quarter. 86.42% of the stock is owned by institutional investors.

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Articles

Analyst Recommendations for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.